ReviewThe Canadian journal of cardiology
Targeted gene therapy for the treatment of heart failure.
Review in The Canadian journal of cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 41 citations in OpenAlex.
- Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration.Journal of cardiovascular development and disease · 2024Review
- Raman spectromics method for fast and label-free genotype screening.Biomedical optics express · 2023Article
- Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics.Frontiers in cardiovascular medicine · 2022Review
- Production and clinical development of nanoparticles for gene delivery.Molecular therapy. Methods & clinical development · 2016Review
- Effectiveness of gene delivery systems for pluripotent and differentiated cells.Molecular therapy. Methods & clinical development · 2015Article
- The road ahead: working towards effective clinical translation of myocardial gene therapies.Therapeutic delivery · 2014Review
- A sight on the current nanoparticle-based gene delivery vectors.Nanoscale research letters · 2014Article
- Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability.Human gene therapy · 2013Review
- Molecular pathogenesis of myocardial remodeling and new potential therapeutic targets in chronic heart failure.Italian journal of pediatrics · 2012Review
- In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfunction in cardiac myosin binding protein C null mice.Circulation. Heart failure · 2012Article
- Gene delivery technologies for cardiac applications.Gene therapy · 2012Review
- Hydrophobic imbalance in the cytoplasmic domain of phospholamban is a determinant for lethal dilated cardiomyopathy.The Journal of biological chemistry · 2012Article
- The shape of things to come: importance of design in nanotechnology for drug delivery.Therapeutic delivery · 2012Review
- The epicardium as a candidate for heart regeneration.Future cardiology · 2012Review
- Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart.Science translational medicine · 2011Article
- The zebrafish as a novel animal model to study the molecular mechanisms of mechano-electrical feedback in the heart.Progress in biophysics and molecular biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chronic heart failure is one of the leading causes of morbidity and mortality in Western countries and is a major financial burden to the health care system. Pharmacologic treatment and implanting devices are the predominant therapeutic approaches. They improve survival and have offered significant improvement in patient quality of life, but they fall short of producing an authentic remedy. Cardiac gene therapy, the introduction of genetic material to the heart, offers great promise in filling this void. In-depth knowledge of the underlying mechanisms of heart failure is, obviously, a prerequisite to achieve this aim. Extensive research in the past decades, supported by numerous methodological breakthroughs, such as transgenic animal model development, has led to a better understanding of the cardiovascular diseases and, inadvertently, to the identification of several candidate genes. Of the genes that can be targeted for gene transfer, calcium cycling proteins are prominent, as abnormalities in calcium handling are key determinants of heart failure. A major impediment, however, has been the development of a safe, yet efficient, delivery system. Nonviral vectors have been used extensively in clinical trials, but they fail to produce significant gene expression. Viral vectors, especially adenoviral, on the other hand, can produce high levels of expression, at the expense of safety. Adeno-associated viral vectors have emerged in recent years as promising myocardial gene delivery vehicles. They can sustain gene expression at a therapeutic level and maintain it over extended periods of time, even for years, and, most important, without a safety risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.